-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma Presents IPH4502 Phase 1 Data, Plans Dose Optimization in Post-EV Urothelial Cancer

PUBT·11/20/2026 16:09:17
Listen to the news
Innate Pharma Presents IPH4502 Phase 1 Data, Plans Dose Optimization in Post-EV Urothelial Cancer
  • Innate Pharma plans to dose the first patient in IPH4502 Phase 1 dose optimization for post-enfortumab vedotin urothelial cancer in H1 2027.
  • Phase 1 escalation showed an unconfirmed disease control rate of 68.4% in post-enfortumab vedotin urothelial cancer; stomatitis was the only dose-limiting toxicity.
  • Lacutamab's TELLOMAK-3 Phase 3 trial has started, with first dosing planned for Q1 2027; an accelerated approval filing is targeted for H2.
  • Monalizumab's PACIFIC-9 Phase 3 high-level data readout is expected in H1 2027.
  • Cash runway is expected to extend through the end of Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.